These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1097 related articles for article (PubMed ID: 34035118)
1. SARS-CoV-2 variants of concern partially escape humoral but not T-cell responses in COVID-19 convalescent donors and vaccinees. Geers D; Shamier MC; Bogers S; den Hartog G; Gommers L; Nieuwkoop NN; Schmitz KS; Rijsbergen LC; van Osch JAT; Dijkhuizen E; Smits G; Comvalius A; van Mourik D; Caniels TG; van Gils MJ; Sanders RW; Oude Munnink BB; Molenkamp R; de Jager HJ; Haagmans BL; de Swart RL; Koopmans MPG; van Binnendijk RS; de Vries RD; GeurtsvanKessel CH Sci Immunol; 2021 May; 6(59):. PubMed ID: 34035118 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 BA.4/5 infection triggers more cross-reactive FcγRIIIa signaling and neutralization than BA.1, in the context of hybrid immunity. Richardson SI; Mzindle N; Motlou T; Manamela NP; van der Mescht MA; Lambson BE; Everatt J; Amoako DG; Balla S; von Gottberg A; Wolter N; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Abdullah F; Rossouw TM; Boswell MT; Ueckermann V; Bhiman JN; Moore PL J Virol; 2024 Jul; 98(7):e0067824. PubMed ID: 38953380 [TBL] [Abstract][Full Text] [Related]
3. Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. Essink BJ; Shapiro C; Isidro MGD; Bradley P; Pragalos A; Bloch M; Santiaguel J; Frias MV; Miyakis S; Alves de Mesquita M; Berrè S; Servais C; Waugh N; Hoffmann C; Baba E; Schönborn-Kellenberger O; Wolz OO; Koch SD; Ganyani T; Boutet P; Mann P; Mueller SO; Ramanathan R; Gaudinski MR; Vanhoutte N Hum Vaccin Immunother; 2024 Dec; 20(1):2408863. PubMed ID: 39422261 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in Vietnam. Duc Dang A; Dinh Vu T; Hai Vu H; Thanh Ta V; Thi Van Pham A; Thi Ngoc Dang M; Van Le B; Huu Duong T; Van Nguyen D; Lawpoolsri S; Chinwangso P; McLellan JS; Hsieh CL; Garcia-Sastre A; Palese P; Sun W; Martinez JL; Gonzalez-Dominguez I; Slamanig S; Manuel Carreño J; Tcheou J; Krammer F; Raskin A; Minh Vu H; Cong Tran T; Mai Nguyen H; Mercer LD; Raghunandan R; Lal M; White JA; Hjorth R; Innis BL; Scharf R Vaccine; 2022 Jun; 40(26):3621-3632. PubMed ID: 35577631 [TBL] [Abstract][Full Text] [Related]
6. Severe acute respiratory syndrome coronavirus 2-specific T-cell responses are induced in people living with human immunodeficiency virus after booster vaccination. Wang X; Li Y; Jin J; Chai X; Ma Z; Duan J; Zhang G; Huang T; Zhang X; Zhang T; Wu H; Cao Y; Su B Chin Med J (Engl); 2024 Nov; 137(22):2734-2744. PubMed ID: 39028115 [TBL] [Abstract][Full Text] [Related]
7. Adjuvants to the S1-subunit of the SARS-CoV-2 spike protein vaccine improve antibody and T cell responses and surrogate neutralization in mice. Becker W; Rebbani K; Duan Z; Valkov E; Bryant S; Ho M; Berzofsky JA; Olkhanud PB Sci Rep; 2024 Nov; 14(1):29609. PubMed ID: 39609527 [TBL] [Abstract][Full Text] [Related]
8. Memory T Cells Subpopulations in a Cohort of COVID-19 Vaccinated or Recovered Subjects. Iuliano M; Mongiovì RM; Parente A; Grimaldi L; Kertusha B; Carraro A; Marocco R; Mancarella G; Del Borgo C; Dorrucci M; Lichtner M; Mangino G; Romeo G Viral Immunol; 2024 Nov; 37(9):440-445. PubMed ID: 39474707 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans. Alter G; Yu J; Liu J; Chandrashekar A; Borducchi EN; Tostanoski LH; McMahan K; Jacob-Dolan C; Martinez DR; Chang A; Anioke T; Lifton M; Nkolola J; Stephenson KE; Atyeo C; Shin S; Fields P; Kaplan I; Robins H; Amanat F; Krammer F; Baric RS; Le Gars M; Sadoff J; de Groot AM; Heerwegh D; Struyf F; Douoguih M; van Hoof J; Schuitemaker H; Barouch DH Nature; 2021 Aug; 596(7871):268-272. PubMed ID: 34107529 [TBL] [Abstract][Full Text] [Related]
10. Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice. Zhu J; Wang Z; Li Y; Zhang Z; Ren S; Wang J; Xie S; Liao Z; Song B; Wu W; Yan F; Peng C J Virol; 2024 Jul; 98(7):e0052124. PubMed ID: 38874361 [TBL] [Abstract][Full Text] [Related]
11. T cell responses to SARS-CoV-2 spike cross-recognize Omicron. Keeton R; Tincho MB; Ngomti A; Baguma R; Benede N; Suzuki A; Khan K; Cele S; Bernstein M; Karim F; Madzorera SV; Moyo-Gwete T; Mennen M; Skelem S; Adriaanse M; Mutithu D; Aremu O; Stek C; du Bruyn E; Van Der Mescht MA; de Beer Z; de Villiers TR; Bodenstein A; van den Berg G; Mendes A; Strydom A; Venter M; Giandhari J; Naidoo Y; Pillay S; Tegally H; Grifoni A; Weiskopf D; Sette A; Wilkinson RJ; de Oliveira T; Bekker LG; Gray G; Ueckermann V; Rossouw T; Boswell MT; Bhiman JN; Moore PL; Sigal A; Ntusi NAB; Burgers WA; Riou C Nature; 2022 Mar; 603(7901):488-492. PubMed ID: 35102311 [TBL] [Abstract][Full Text] [Related]
12. Polysaccharide, Conjugate, and mRNA-based Vaccines are Immunogenic in Patients with Netherton Syndrome. Nouwen AEM; Zaeck LM; Schappin R; Geers D; Gommers L; Bogers S; Dik WA; Pasmans SGMA; GeurtsvanKessel CH; de Vries RD; Dalm VASH J Clin Immunol; 2024 Oct; 45(1):36. PubMed ID: 39476295 [TBL] [Abstract][Full Text] [Related]
13. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Kaplonek P; Fischinger S; Cizmeci D; Bartsch YC; Kang J; Burke JS; Shin SA; Dayal D; Martin P; Mann C; Amanat F; Julg B; Nilles EJ; Musk ER; Menon AS; Krammer F; Saphire EO; Andrea Carfi ; Alter G Immunity; 2022 Feb; 55(2):355-365.e4. PubMed ID: 35090580 [TBL] [Abstract][Full Text] [Related]
14. Comparison of antibody responses of heterologous and homologous Covid-19 booster vaccination: an observational study. Rizvi NB; Bibi M; Rana MZ; Zaffar S; Farooq H Front Immunol; 2024; 15():1448408. PubMed ID: 39606247 [TBL] [Abstract][Full Text] [Related]
15. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: A prospective cohort study. van Gils MJ; Lavell A; van der Straten K; Appelman B; Bontjer I; Poniman M; Burger JA; Oomen M; Bouhuijs JH; van Vught LA; Slim MA; Schinkel M; Wynberg E; van Willigen HDG; Grobben M; Tejjani K; van Rijswijk J; Snitselaar JL; Caniels TG; ; Vlaar APJ; Prins M; de Jong MD; de Bree GJ; Sikkens JJ; Bomers MK; Sanders RW PLoS Med; 2022 May; 19(5):e1003991. PubMed ID: 35580156 [TBL] [Abstract][Full Text] [Related]
16. Factors associated with immune responses to SARS-CoV-2 vaccination in individuals with autoimmune diseases. Anderson E; Powell M; Yang E; Kar A; Leung TM; Sison C; Steinberg R; Mims R; Choudhury A; Espinosa C; Zelmanovich J; Okoye NC; Choi EJ; Marder G; Narain S; Gregersen PK; Mackay M; Diamond B; Levy T; Zanos TP; Khosroshahi A; Sanz I; Luning Prak ET; Bar-Or A; Merrill J; Arriens C; Pardo G; Guthridge J; James J; Payne A; Utz PJ; Boss JM; Aranow C; Davidson A JCI Insight; 2024 Jun; 9(13):. PubMed ID: 38833310 [TBL] [Abstract][Full Text] [Related]
17. Imprinting of serum neutralizing antibodies by Wuhan-1 mRNA vaccines. Liang CY; Raju S; Liu Z; Li Y; Asthagiri Arunkumar G; Case JB; Scheaffer SM; Zost SJ; Acreman CM; Gagne M; Andrew SF; Carvalho Dos Anjos DC; Foulds KE; McLellan JS; Crowe JE; Douek DC; Whelan SPJ; Elbashir SM; Edwards DK; Diamond MS Nature; 2024 Jun; 630(8018):950-960. PubMed ID: 38749479 [TBL] [Abstract][Full Text] [Related]
18. Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Cele S; Gazy I; Jackson L; Hwa SH; Tegally H; Lustig G; Giandhari J; Pillay S; Wilkinson E; Naidoo Y; Karim F; Ganga Y; Khan K; Bernstein M; Balazs AB; Gosnell BI; Hanekom W; Moosa MS; ; ; Lessells RJ; de Oliveira T; Sigal A Nature; 2021 May; 593(7857):142-146. PubMed ID: 33780970 [TBL] [Abstract][Full Text] [Related]